<DOC>
	<DOCNO>NCT00000675</DOCNO>
	<brief_summary>To study safety pharmacokinetics ( blood level ) recombinant human CD4 immunoglobulin ( rCd4-IgG ) patient AIDS AIDS relate complex ( ARC ) fail decline therapy zidovudine ( AZT ) . An additional goal study obtain preliminary indication antiviral effect Cd4-IgG patient AIDS ARC . Other approach addition exist treatment HIV infection need evaluate . One approach may block HIV infection interrupt assembly virus within cell bud virus membrane infect cell . In addition , block attachment HIV cellular receptor may offer another point attack . HIV bind CD4 receptor target T4 lymphocyte envelope glycoprotein virus ( gp120 ) capable high affinity bind CD4 . Any agent prevents attachment gp120 CD4 receptor able block virus transmission spread . Recently , scientist succeed produce highly purify recombinant soluble human CD4 . Recombinant CD4 capable binding HIV envelope protein ( gp120 ) inhibit HIV infectivity test tube study . Potential therapeutic benefit patient HIV infection could derive either biologic effect . In order extend length time rCD4 stay body , compound modify combine human immunoglobulin IgG1 class ( IgG ) .</brief_summary>
	<brief_title>A Phase I Study Safety Pharmacokinetics Recombinant Human CD4 Immunoglobulin ( rCd4-IgG ) Administered Intravenous Bolus Patients With AIDS AIDS Related Complex</brief_title>
	<detailed_description>Other approach addition exist treatment HIV infection need evaluate . One approach may block HIV infection interrupt assembly virus within cell bud virus membrane infect cell . In addition , block attachment HIV cellular receptor may offer another point attack . HIV bind CD4 receptor target T4 lymphocyte envelope glycoprotein virus ( gp120 ) capable high affinity bind CD4 . Any agent prevents attachment gp120 CD4 receptor able block virus transmission spread . Recently , scientist succeed produce highly purify recombinant soluble human CD4 . Recombinant CD4 capable binding HIV envelope protein ( gp120 ) inhibit HIV infectivity test tube study . Potential therapeutic benefit patient HIV infection could derive either biologic effect . In order extend length time rCD4 stay body , compound modify combine human immunoglobulin IgG1 class ( IgG ) . Each patient receive rCd4-IgG fix dose level weekly intravenous bolus 12 week . Four patient ( two per center ) enter dose level start low dose . Dose escalation proceeds maximum tolerate dose ( MTD ) define . AMENDED : Includes , 891201 , ancillary study entitle `` A Study Recombinant CD4-Immunoglobulin G ( CD4-IgG ) Levels Cerebral Spinal Fluid rCD4-IgG Administered Intravenous Bolus Patients With AIDS AIDS-Related Complex '' . This involve select patient , discretion Investigator . AMENDED : 900110 To increase dose frequency administration rCD4-IgG , base preliminary result pharmacokinetic analysis Phase I study human . Each patient receive rCD4-IgG therapy fix dose level 1x , 2x , 3x weekly intravenous bolus 12 week . Follow-up extend 8 week . Total target accrual 25 - 28 week . AMENDED : 900824 Extension Phase I study safety efficacy CD4-IgG patient HIV infection . Each patient receive one two fixed dos IV bolus injection twice per week 12 week . 20 30 patient enrol . Pharmacokinetics evaluate . Clinical safety antiviral effect assay .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>CD4 Immunoadhesins</mesh_term>
	<criteria>Inclusion Criteria Patients must fulfill follow criterion : Diagnosis AIDS AIDSrelated complex , accord CDC criterion , previously document HIV seropositive individual . Failure tolerate respond zidovudine ( AZT ) therapy HIV infection decision decline therapy . Willingness abstain experimental therapy HIV infection study period . Life expectancy least 3 month . Patients must able sign write informed consent form . Exclusion Criteria Coexisting Condition : Patients follow exclude : Serious active opportunistic infection malignancy specifically allow . Concurrent Medication : Excluded : Oral intravenous acyclovir herpes . Zidovudine ( AZT ) . Interferon . Corticosteroids . Nonsteroidal antiinflammatory agent ( NSAIDS ) . Intravenous acyclovir . Other known immunomodulatory agent . Other experimental therapy . Patients follow exclude : Serious active opportunistic infection malignancy specifically allow . Prior Medication : Excluded within 4 week study entry : Zidovudine ( AZT ) . Chemotherapy . Immunomodulatory agent . Other experimental therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1991</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>IgG</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antigens , CD4</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Carrier Proteins</keyword>
</DOC>